 |
The
Economic Costs of Undiagnosed Diabetes |
| |
The estimated economic costs of undiagnosed
diabetes mellitus in 2007 is $18 billion ($2864 per person with
UDM), including medical costs of $11 billion and indirect costs
of $7 billion (Population Health Management) |
| |
|
|
Lantus
insulin: a possible link with cancer which requires further investigation |
| |
The European Association for the Study of Diabetes
(EASD) today makes an urgent call for more research into a possible
link between use of insulin glargine (an insulin analogue, brand
name Lantus) and increased risk of cancer, following evidence from
studies in Germany, Sweden and Scotland (Diabetelogia) |
| |
|
|
Possible
Link Between Insulin Glargine and Cancer |
| |
Statement from the American Diabetes Association
Related to Studies Published in Diabetelogia Suggesting Possible
Link Between Insulin Glargine and Cancer (Diabetes Pro) |
| |
|
|
The
effect of glucose variability on the long-term risk of microvascular
complications in type 1 diabetes |
| |
Glucose variability in the Diabetes Control
and Complications Trial (DCCT) did not predict the development
of retinopathy or nephropathy by Epidemiology of Diabetes Interventions
and Complications (EDIC) year 4 (Diabetes Care) |
| |
|
|
Combined
effects of obesity and type 2 diabetes contribute to increased
breast cancer risk in premenopausal women |
| |
Obesity and type 2 diabetes, owing to their
effects on adipocytokines and inflammatory mediators, contribute
to increased breast cancer risk in premenopausal women (Cardiovascular
Diabetology) |
| |
|
|
Epidemiology
and correlates of weight worry in the multinational Diabetes
Attitudes, Wishes and Needs study |
| |
High weight worry was common among adults with
diabetes and associated with several adverse outcomes, including
multiple indicators of diabetes-related distress, poor physical
and psychological well-being, and regimen non-adherence (Informa) |
| |
|
|
Erythropoietin
during hypoglycaemia in type 1 diabetes: Relation to basal renin-angiotensin
system activity and cognitive functionstar, open |
| |
Hypoglycaemia triggers a rise in plasma erythropoietin
in patients with type 1 diabetes. The response is influenced by
basal RAS activity. Erythropoietin may carry a neuroprotective
potential during hypoglycaemia (Diabetes Research and Clinical
Practice) |
| |
|
|
Effects
of Sleep Fragmentation on Glucose Metabolism in Normal Subjects |
| |
Fragmentation of sleep across all stages is
associated with a decrease in insulin sensitivity and glucose effectiveness.
Increases in sympathetic nervous system and adrenocortical activity
likely mediate the adverse metabolic effects of poor sleep quality
(Chest) |
| |
|
|
Spherix
says diabetes drug shows promise, shares soar |
| |
Spherix Inc said its experimental type 2 diabetes
drug, Naturlose, showed positive preliminary data from a mid-stage
study, driving its shares up more than two-fold (CNBC) |
| |
|
|
Takeda's
Diabetes Drug Delayed |
| |
Takeda Pharmaceutical Co. said Saturday the
U.S. Food and Drug Administration's guidance to conduct an additional
safety study on its new diabetes drug SYR-322 will likely to delay
the drug's launch by "at least two years." (Wall Street Journal) |
| |
|
|
Glenmark’s
novel molecule for Diabetes, Melogliptin to enter phase III trials |
| |
In the recently completed 12 week Phase IIb
clinical trial in 494 patients with type 2 diabetes mellitus, ‘Melogliptin’, Glenmark’s investigational medicine from a new class of diabetes treatments called dipeptidyl
peptidase 4 (DPP-4) inhibitors, improved glycemic control in patients
with type 2 diabetes mellitus and exhibited excellent safety and
tolerability profile (Glenmark Pharmaceuticals) |
| |
|
|
Insulin
Detemir added to Provincial Drug Formulary |
| |
The Canadian Diabetes Association applauds the
Government of Ontario for increasing access to insulin detemir
for Ontarians living with diabetes. Insulin detemir, also known
as Levemir has been added to the Ontario Drug Formulary, effective
June 23 (Canadian Diabetes Association) |
| |
|
